



## Cholesterol-Lowering Program Update

- Pathology analysis reveals adverse signal observed in final toxicology study, precluding Nyrada's drug candidate from clinical evaluation in Cholesterol-Lowering
- Phase I/IIa study deferred

**Sydney 26<sup>th</sup> June 2023:** Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announced that while the Company's cholesterol-lowering drug candidate returned no unusual safety signals in all but one key study, due to an adverse signal observed in a Good Laboratory Practice (GLP) toxicology study, the Company's drug candidate will not be taken forward into the planned Phase I/IIa clinical trial.

Nyrada was advised by the US Contract Research Organisation (CRO) engaged to conduct the preclinical safety and toxicology studies that during the later stages of the recently completed 28-day *in vivo* GLP toxicology study, adverse pathology findings in response to the Company's drug candidate were observed in a number of animal subjects.

After seeking advice from Nyrada's consultant toxicologist, and following further discussions with the US CRO, it was determined that the Company's clinical drug candidate is not suitable to be advanced into a first-in-human study.

**Nyrada CEO, James Bonnar said,** "The team and I were encouraged by preliminary study readouts in the lead-up to completion of the 28-day toxicology study. The observed adverse pathology findings were unexpected, with our drug candidate successfully passing safety and toxicology studies except for one.

"Although this development means a temporary delay in the program, we remain committed to our mission to develop an oral small molecule PCSK9 inhibitor drug, as we believe it to be the optimal approach to lowering high cholesterol.

Nyrada has a cash position of A\$6.6 million at 31 March 2023.

Nyrada will provide an update to the market as further information becomes available.

-ENDS-

### About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically



traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.*

**Investor & Corporate Enquiries:**

Laura Vize

Investor Relations Manager

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

**Company Secretary:**

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media Enquiries:**

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

**Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.